Ascendis Pharma ASND has outperformed the market over the past 15 years by 20.52% on an annualized basis producing an average ...

According to Benzinga Pro, Ascendis Pharma's peer group average for short interest as a percentage of float is 5.60%, which ...

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company ...

Endocrine-disease-focused Visen Pharmaceuticals is making its public market debut in Hong Kong, filing papers for an $86.5 ...

JPMorgan raised the firm’s price target on Ascendis Pharma (ASND) to $200 from $168 and keeps an Overweight rating on the shares. The firm ...

A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) had its target price raised by investment analysts at JPMorgan Chase & Co ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of ...

Shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) have received an average rating of “Moderate Buy” from the fourteen brokerages that are covering the stock, MarketBeat reports.

COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual ...